Tissue plasminogen activator is a ligand of cation-independent mannose 6-phosphate receptor and consists of glycoforms that contain mannose 6-phosphate. 2021

James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
Department of Biochemistry, Medical College of Wisconsin, 8701 W. Watertown Plank Rd, Milwaukee, WI, 53226, USA.

Plasmin is the key enzyme in fibrinolysis. Upon interaction with plasminogen activators, the zymogen plasminogen is converted to active plasmin. Some studies indicate plasminogen activation is regulated by cation-independent mannose 6-phosphate receptor (CI-MPR), a protein that facilitates lysosomal enzyme trafficking and insulin-like growth factor 2 downregulation. Plasminogen regulation may be accomplished by CI-MPR binding to plasminogen or urokinase plasminogen activator receptor. We asked whether other members of the plasminogen activation system, such as tissue plasminogen activator (tPA), also interact with CI-MPR. Because tPA is a glycoprotein with three N-linked glycosylation sites, we hypothesized that tPA contains mannose 6-phosphate (M6P) and binds CI-MPR in a M6P-dependent manner. Using surface plasmon resonance, we found that two sources of tPA bound the extracellular region of human and bovine CI-MPR with low-mid nanomolar affinities. Binding was partially inhibited with phosphatase treatment or M6P. Subsequent studies revealed that the five N-terminal domains of CI-MPR were sufficient for tPA binding, and this interaction was also partially mediated by M6P. The three glycosylation sites of tPA were analyzed by mass spectrometry, and glycoforms containing M6P and M6P-N-acetylglucosamine were identified at position N448 of tPA. In summary, we found that tPA contains M6P and is a CI-MPR ligand.

UI MeSH Term Description Entries
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008360 Mannosephosphates Phosphoric acid esters of mannose.
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
May 1989, The Journal of biological chemistry,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
May 1989, The Journal of biological chemistry,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
January 2010, Biochemistry,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
October 1998, Biochemistry,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
June 2015, Glycobiology,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
July 1995, FEBS letters,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
February 1995, FEBS letters,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
April 2007, Journal of leukocyte biology,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
February 1988, The Journal of biological chemistry,
James J Miller, and Richard N Bohnsack, and Linda J Olson, and Mayumi Ishihara, and Kazuhiro Aoki, and Michael Tiemeyer, and Nancy M Dahms
September 1988, Journal of cellular biochemistry,
Copied contents to your clipboard!